Prospector
Profile
07.1133
|
| |
| Somanta Pharmaceuticals, Inc. |
NAICS |
541710 |
| 19200 Von Karman Avenue, Suite 400
Irvine, CA 92612 |
Description |
Biotechnology |
| (949) 477-8090 |
Employees |
3 |
| http://www.somanta.com/About_whoweare.htm |
Revenue |
(mil) |
0.0010 |
| |
Income |
(mil) |
-7.4950 |
| |
Assets |
(mil) |
0.0670 |
| |
Liability |
(mil) |
8.2440 |
| |
(for the year ended 2007-04-30) |
| |
|
Category:
Audit Concerns
|
| |
|
Event:
Stonefield Josephson, Inc. expressed doubts on the ability of Somanta Pharmaceuticals, Inc. to continue as a going concern after auditing its financial statements. The Company has incurred a net loss of $7,495,637 for the year ended April 30, 2007 and losses of $15,796,145 since inception. The Company expects operating losses to increase for at least the next several years as it pursues the clinical development of its lead product candidates and expand its discovery and development pipeline.
|
| |
|
Intellectual Property:
The Company currently owns one patent that relates to Alchemix, together with its foreign counterpart in the European Union. It has also filed a patent application in the United States and the European Union related on Prodrax. Its intellectual property related to Angiolix consists of an exclusive sub-license from Immunodex, Inc. to practice the patents that relate to Angiolix in the field of the treatment of cancer. The intellectual property related to PB consists of an exclusive sub-license from Virium Pharmaceuticals, Inc. to practice the patents that relate to PB in the field of the treatment of cancer outside of North America. [SEC Filing 10-KSB 07-12-07]
|
| |
|
Description:
The Company develops drugs primarily for the treatment of cancer.
|
| |
|
Officers:
Terrance J. Bruggeman (Chair, Acting CFO & Dir.); Agamemnon A. Epenetos (Pres., CEO & Dir.); Michael R. D Ashton (Dir.); Jeffrey B. Davis (Dir.); John R. Gibson (Dir.); Kathleen H. Van Sleen (Dir.)
|
| |
|
Auditor:
Stonefield Josephson, Inc.
|
| |
|
Securities:
Common Stock-Symbol SMPM.OB; OTC BB;
14,292,603 common shares outstanding as of June 28, 2007.
|
| |
| |
| |
| return to main page |
